Blockade of the CD40-CD154 costimulatory pathway can inhibit CD4(+) T cell-mediated alloimmune responses. The aim of this study was to define the in vivo requirement for CD40-CD154 costimulation by CD4(+) T cells that respond to alloantigen following direct recognition. We used TCR-transgenic CD4(+) T cells that are reactive to the MHC class II alloantigen, H2A(s). An experimental in vivo model was established that allowed direct comparison of the fate of a trace population of H2A(s)-reactive CD4(+) T cells when challenged with different forms of H2A(s+) alloantigen under conditions of CD40-CD154 costimulation blockade. In this study, we demonstrate that an i.v. infusion of H2A(s+) leukocytes in combination with anti-CD154 therapy rapidly d...
SummaryMHC alloantigen is recognized by two pathways: “directly,” intact on donor cells, or “indirec...
CD154/CD40 blockade combined with donor specific transfusion remains one of the most effective thera...
Blockade of costimulatory signals is a promising therapeutic target to prevent allograft rejection. ...
Blockade of the CD40-CD154 costimulatory pathway can inhibit CD4(+) T cell-mediated alloimmune respo...
Blockade of CD40-CD154 interactions can facilitate long-term allograft acceptance in selected rodent...
The major obstacle still facing long-term graft acceptance is the strong T cell mediated immune resp...
A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disea...
The major obstacle still facing long-term graft acceptance is the strong T cell mediated immune resp...
MHC alloantigen is recognized by two pathways: "directly," intact on donor cells, or "indirectly," a...
Solid organ transplantation is the treatment of choice for end-stage organ failure. Understanding ev...
Solid organ transplantation is the treatment of choice for end-stage organ failure. Understanding ev...
A two-element protocol consisting of one donor-specific transfusion (DST) plus a brief course of ant...
BACKGROUND: The effectiveness of anti-CD154 monoclonal antibodies in prolonging the survival of mous...
Summary: MHC alloantigen is recognized by two pathways: “directly,” intact on donor cells, or “indir...
The CD40-CD40 ligand (CD40L) interaction is a key event in the initiation of an adaptive immune resp...
SummaryMHC alloantigen is recognized by two pathways: “directly,” intact on donor cells, or “indirec...
CD154/CD40 blockade combined with donor specific transfusion remains one of the most effective thera...
Blockade of costimulatory signals is a promising therapeutic target to prevent allograft rejection. ...
Blockade of the CD40-CD154 costimulatory pathway can inhibit CD4(+) T cell-mediated alloimmune respo...
Blockade of CD40-CD154 interactions can facilitate long-term allograft acceptance in selected rodent...
The major obstacle still facing long-term graft acceptance is the strong T cell mediated immune resp...
A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disea...
The major obstacle still facing long-term graft acceptance is the strong T cell mediated immune resp...
MHC alloantigen is recognized by two pathways: "directly," intact on donor cells, or "indirectly," a...
Solid organ transplantation is the treatment of choice for end-stage organ failure. Understanding ev...
Solid organ transplantation is the treatment of choice for end-stage organ failure. Understanding ev...
A two-element protocol consisting of one donor-specific transfusion (DST) plus a brief course of ant...
BACKGROUND: The effectiveness of anti-CD154 monoclonal antibodies in prolonging the survival of mous...
Summary: MHC alloantigen is recognized by two pathways: “directly,” intact on donor cells, or “indir...
The CD40-CD40 ligand (CD40L) interaction is a key event in the initiation of an adaptive immune resp...
SummaryMHC alloantigen is recognized by two pathways: “directly,” intact on donor cells, or “indirec...
CD154/CD40 blockade combined with donor specific transfusion remains one of the most effective thera...
Blockade of costimulatory signals is a promising therapeutic target to prevent allograft rejection. ...